

Press Release

Media Contact
Martin Kunze
T +49 6172 609-2115
martin.kunze@fresenius.com

**Contact for analysts and
investors**
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com

www.freseniusmedicalcare.com

April 24, 2018

Fresenius Medical Care wins Red Dot design award for advanced bloodline system used in hemodialysis

Fresenius Medical Care, the world's largest provider of dialysis products and services, has won the Red Dot Award: Product Design for the company's 6008 CAREset. This advanced all-in-one disposable with pre-connected bloodlines combines with the 6008 dialysis machine to form the 6008 CAREsystem. The 6008 CAREset was developed for use in all hemodialysis treatments, including Fresenius Medical Care's advanced HighVolumeHDF dialysis therapy.

The Red Dot Award for outstanding international product design has been presented annually since 1955 by the Design Center North Rhine-Westphalia in Essen, Germany. More than 6,300 products from companies in 59 countries were entered into this year's competition.

"The 6008 CAREsystem stands for reduced complexity, and minimizes the number of handling steps during dialysis," said Dr. Olaf Schermeier, Fresenius Medical Care's Chief Executive Officer for Global Research and Development. "The innovative design of the 6008 CAREset makes a key contribution to this. Because the bloodlines are pre-connected, the medical staff has more time to provide direct patient care. We are delighted about the recognition that this internationally renowned award will bring."

Handling steps are reduced not only during dialysis, but during the set-up and disconnection phases before and after each treatment. The 6008 CAREset is simply inserted into the dialysis machine, eliminating the need to manually connect the

bloodlines: This limits potential connection errors, which makes treatments safer. And in addition to being more cost efficient, the reduced amount of waste generated during a treatment makes the 6008 CAREsystem environmentally friendly.

Dialysis machines, bloodline systems and dialyzers – the latter often dubbed “artificial kidneys” because this is where the blood is actually cleaned – are the most important products for treating chronic kidney disease. During treatment, the dialysis machine pumps the patient’s blood through bloodlines, monitors its circulation through the dialyzer, and adds anti-coagulants. Treatments are generally carried out three times weekly, and take between three and six hours each.

About half of all dialysis machines and dialyzers sold worldwide are produced by Fresenius Medical Care.

More information about the Red Dot Award is available at <https://en.red-dot.org>.

Note to the media: Images of the 6008 CAREsystem can be found at <https://tinyurl.com/ybvzx9bj>.

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,752 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 320,960 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.